Laventair
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT00950807)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Muscarinic acetylcholine receptorANTAGONIST
Muscarinic acetylcholine receptor antagonist
- Muscarinic acetylcholine receptor M3 (CHRM3) ↗
- Muscarinic acetylcholine receptor M4 (CHRM4) ↗
- Muscarinic acetylcholine receptor M1 (CHRM1) ↗
- Muscarinic acetylcholine receptor M5 (CHRM5) ↗
- Muscarinic acetylcholine receptor M2 (CHRM2) ↗
- Muscarinic acetylcholine receptor M2
- Muscarinic acetylcholine receptor M1
- Muscarinic acetylcholine receptor M4
- Muscarinic acetylcholine receptor M5
- Muscarinic acetylcholine receptor M3
- Muscarinic acetylcholine receptors; M2 & M3
- Muscarinic acetylcholine receptors; M1 & M2
- Muscarinic acetylcholine receptor M1/M5 chimeric protein
- Muscarinic acetylcholine receptor M1 and M3
- Muscarinic acetylcholine receptor M2 and M4
- Muscarinic acetylcholine receptor M2 and M5
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk573179
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00950807 | Phase 2 | Sep 1, 2009 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1